期刊文献+

PTD-HBcAg融合蛋白诱导HBV特异性免疫反应的研究

The Experimental Study of Specific Immune Response Induced by PTD-HBcAg Fusion Protein
原文传递
导出
摘要 目的观察PTD-HBcAg融合蛋白免疫BALB/c小鼠后的体液免疫与细胞免疫效果。方法目的蛋白(PTD-HBcAg)、阳性对照蛋白(HBcAg)和阴性对照分别与等体积的弗氏完全佐剂乳化免疫小鼠,第21天以不完全弗氏佐剂乳化同法加强免疫,第28天ELISA法检测HBcAb滴度,流式细胞仪检测HBV特异性IFN-γ+、CD8+T淋巴细胞水平。结果PTD-HBcAg融合蛋白能够诱导产生较高水平HBcAb;与阳性蛋白对照组[(1.45±0.19)%,(2.19±0.04)%和(4.32±1.04)%]和阴性对照组相比,PTD-HBcAg融合蛋白组[(2.64±0.21)%,(3.50±0.50)%和(6.85±1.3)%]诱导的HBV特异性CD8+T淋巴细胞水平明显增高(P<0.05)。结论PTD-HBcAg融合蛋白具有体液免疫与细胞免疫效果,为治疗性乙肝疫苗的开发提供了一定的实验基础。 Objective To observe the humoral and cellular immune effects of PTD-HBcAg fusion protein in mice.Methods BALB/c mice were subcutaneously immunized at the tail base with 100 μl of freshly prepared emulsion containing PTD-HBcAg,HBcAg,PTD,PBS and an equal volume of CFA.Mice were equally booster immunized with the antigen mixture emulsified in IFA,21 days later.Sera were collected to test HBcAb and splenocytes were prepared to study IFN-γ+,CD8+ T lymphocytes on day 28.Results PTD-HBcAg fusion protein could induce higher levels of HBcAb;The amount of specific CD8+ T lymphocytes induced by PTD-HBcAg was much more than that induced by others[(2.64±0.21)%,(3.50±0.50)%,(6.85±1.30)% vs(1.45±0.19)%,(2.19±0.04)%,(4.32±1.04)%;P0.05].Conclusion PTD-HBcAg fusion protein showed good humoral and cellular immune effects,which provided a experimental basis for the development of therapeutic hepatitis B vaccine.
出处 《中华全科医学》 2009年第12期1262-1264,共3页 Chinese Journal of General Practice
基金 国家自然科学基金资助项目(30571669)
关键词 PTD-HBcAg 融合蛋白 细胞免疫 体液免疫 慢性乙型肝炎 PTD-HBcAg Fusion protein Immune effect Chronic hepatitis B
  • 相关文献

参考文献12

二级参考文献53

  • 1杨小华,张立煌,曹雪涛.可溶性细胞因子受体与疾病发生发展以及治疗的研究进展[J].国外医学(免疫学分册),2005,28(1):48-51. 被引量:6
  • 2Bertoletti A, Maini M, Williams R. Role of hepatitis B virus specific cytotoxic T cells in liver damage and viral control. Antiviral Res, 2003,60 : 61-66.
  • 3Webster GJ, Bertoletti A. Control or persistence of hepatitis B virus: the critical role of initial host-virus interactions. Immunol Cell Biol, 2002,80: 101-105.
  • 4Connolly JB. Lentiviruses in gene therapy clinical research. Gene Ther, 2002, 9: 1730-1734.
  • 5Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem, 1997,272: 16010-16017.
  • 6Dietz GP, Bahr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci, 2004, 27: 85-131.
  • 7Dietz GP, Kilic E, Pahr M. Inhibition of neuronal apoptosis in vitro and in vivo using TAT -mediated protein transduction. Mol Cell Neurosci, 2002,21: 29-37.
  • 8Jung MC, Pape GR. Immunology of hepatitis B infection. Lancet Infect Dis, 2002, 2: 43-50.
  • 9Dominguez-Bendala J, Klein D, Ribeiro M, et al. TAT- mediated neurogenin 3 protein transduction stimulates pancreatic endocrine differentiation in vitro. Diabetes, 2005, 54: 720-726.
  • 10Chauhan A, Tikoo A, Kapur AK, et al. The taming of the cell penetrating domain of the HIV Tat : myths and realities [ J ]. Control Release ,2007,117 ( 2 ) : 148 - 162.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部